Condition: Vulva Cancer · Sponsor: National Cancer Institute, Naples
MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer. 80 patients will be overall enrolled in the study.Three cohorts are planned
This description comes directly from the study's public registry record.
Clorinda Schettino, MD · +39 081 - 17770276 · c.schettino@istitutotumori.na.it
Sandro Pignata, MD, PhD · 39 081-17770755 · s.pignata@istitutotumori.na.it
Always discuss trial participation with your own doctor first.
| Nation Cancer Institute of Naples, Division of Medical Oncology - Uro-Gynecology Department, Naples | Naples, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07290894